These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 16483865)

  • 1. Pharmacologic management of overactive bladder: practical options for the primary care physician.
    Staskin DR; MacDiarmid SA
    Am J Med; 2006 Mar; 119(3 Suppl 1):24-8. PubMed ID: 16483865
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Maximizing anticholinergic therapy for overactive bladder: has the ceiling been reached?
    MacDiarmid SA
    BJU Int; 2007 Jun; 99 Suppl 3():8-12. PubMed ID: 17488367
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Using anticholinergics to treat overactive bladder: the issue of treatment tolerability.
    Staskin DR; MacDiarmid SA
    Am J Med; 2006 Mar; 119(3 Suppl 1):9-15. PubMed ID: 16483863
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Symptom bother and health-related quality of life outcomes following solifenacin treatment for overactive bladder: the VESIcare Open-Label Trial (VOLT).
    Garely AD; Kaufman JM; Sand PK; Smith N; Andoh M
    Clin Ther; 2006 Nov; 28(11):1935-46. PubMed ID: 17213014
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Management of overactive bladder and urge urinary incontinence in the elderly patient.
    Erdem N; Chu FM
    Am J Med; 2006 Mar; 119(3 Suppl 1):29-36. PubMed ID: 16483866
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and tolerability of solifenacin in elderly subjects with overactive bladder syndrome: a pooled analysis.
    Wagg A; Wyndaele JJ; Sieber P
    Am J Geriatr Pharmacother; 2006 Mar; 4(1):14-24. PubMed ID: 16730617
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy of solifenacin in patients previously treated with tolterodine extended release 4 mg: results of a 12-week, multicenter, open-label, flexible-dose study.
    Chancellor MB; Zinner N; Whitmore K; Kobashi K; Snyder JA; Siami P; Karram M; Laramée C; Capo' JP; Seifeldin R; Forero-Schwanhaeuser S; Nandy I
    Clin Ther; 2008 Oct; 30(10):1766-81. PubMed ID: 19014833
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Anticholinergic drugs in overactive bladder].
    Muhlstein J; Deval B
    Gynecol Obstet Fertil; 2008 Jan; 36(1):90-6. PubMed ID: 18178506
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Solifenacin for overactive bladder with incontinence: symptom bother and health-related quality of life outcomes.
    Garely AD; Lucente V; Vapnek J; Smith N
    Ann Pharmacother; 2007 Mar; 41(3):391-8. PubMed ID: 17341526
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Short- and long-term efficacy of solifenacin treatment in patients with symptoms of mixed urinary incontinence.
    Staskin DR; Te AE
    BJU Int; 2006 Jun; 97(6):1256-61. PubMed ID: 16686722
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Solifenacin for overactive bladder in women unsuccessfully treated with immediate release oxybutynin: a pilot study.
    Wong C; Duggan P
    J Obstet Gynaecol; 2009 Jan; 29(1):31-4. PubMed ID: 19280492
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Solifenacin in the management of the overactive bladder syndrome.
    Robinson D; Cardozo L
    Int J Clin Pract; 2005 Oct; 59(10):1229-36. PubMed ID: 16178992
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Oxybutynin transdermal system improves the quality of life in adults with overactive bladder: a multicentre, community-based, randomized study.
    Sand P; Zinner N; Newman D; Lucente V; Dmochowski R; Kelleher C; Dahl NV
    BJU Int; 2007 Apr; 99(4):836-44. PubMed ID: 17187655
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Solifenacin succinate for the treatment of symptoms of overactive bladder.
    Maniscalco M; Singh-Franco D; Wolowich WR; Torres-Colón R
    Clin Ther; 2006 Sep; 28(9):1247-72. PubMed ID: 17062299
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tolterodine extended release improves overactive bladder symptoms in men with overactive bladder and nocturia.
    Kaplan SA; Roehrborn CG; Dmochowski R; Rovner ES; Wang JT; Guan Z
    Urology; 2006 Aug; 68(2):328-32. PubMed ID: 16904446
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Electromotive drug-administration: a pilot study for minimal-invasive treatment of therapy-resistant idiopathic detrusor overactivity.
    Bach P; Wormland RT; Möhring C; Goepel M
    Neurourol Urodyn; 2009; 28(3):209-13. PubMed ID: 19205067
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Muscarinic receptor antagonists for overactive bladder.
    Abrams P; Andersson KE
    BJU Int; 2007 Nov; 100(5):987-1006. PubMed ID: 17922784
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Transdermal oxybutynin: sticking to the facts.
    Cartwright R; Cardozo L
    Eur Urol; 2007 Apr; 51(4):907-14; discussion 914. PubMed ID: 17157979
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and tolerability of tolterodine extended-release in men with overactive bladder and urgency urinary incontinence.
    Roehrborn CG; Abrams P; Rovner ES; Kaplan SA; Herschorn S; Guan Z
    BJU Int; 2006 May; 97(5):1003-6. PubMed ID: 16643482
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The causes and consequences of overactive bladder.
    Miller J; Hoffman E
    J Womens Health (Larchmt); 2006 Apr; 15(3):251-60. PubMed ID: 16620184
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.